The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer

Biochemical Journal

Volumn 463, Issue 1, 2014, Pages 157-165

  Teo, Katy ^a   Brunton, Valerie G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autotaxin; Breast cancer; Lysophosphatidic acid; Metastasis; Therapy

Indexed keywords

AUTOTAXIN; INTERLEUKIN 1; INTERLEUKIN 4; LYSOPHOSPHATIDIC ACID; SPHINGOSINE KINASE 1; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; LYSOPHOSPHOLIPID; PHOSPHODIESTERASE; TUMOR PROTEIN;

ANGIOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; CHROMOSOME 8; FIBROSING ALVEOLITIS; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; NEGATIVE FEEDBACK; NEUROPATHIC PAIN; NON SMALL CELL LUNG CANCER; NONHUMAN; OPEN ANGLE GLAUCOMA; PHYSIOLOGY; PROFESSIONAL KNOWLEDGE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; FEMALE; METABOLISM; PATHOLOGY; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 84906971816     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140680     Document Type: Review

References (111)

1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D. and Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11, International Agency for Research on Cancer, France, http://globocan.iarc.fr.
2. American Cancer Society (2012) Breast Cancer Facts & Figures 2011-2012, American Cancer Society, U.S.A. http://www.cancer.org/research/cancerfactsfigures/breastcancerfactsfigures/breast-cancer-facts-and-figures-2011-2012.
3. Moolenaar, W. H. (2002) Lysophospholipids in the limelight: Autotaxin takes center stage. J. Cell Biol. 158, 197-199 CrossRef PubMed.
4. Mills, G. B. and Moolenaar, W. H. (2003) The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 3, 582-591 CrossRef PubMed.
5. Nam, S. W., Clair, T., Kim, Y. S., McMarlin, A., Schiffmann, E., Liotta, L. A. and Stracke, M. L. (2001) Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61, 6938-6944 PubMed.
6. Umezu-Goto, M., Kishi, Y., Taira, A., Hama, K., Dohmae, N., Takio, K., Yamori, T., Mills, G. B., Inoue, K., Aoki, J. and Arai, H. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227-233 CrossRef PubMed.
7. Gaetano, C. G., Samadi, N., Tomsig, J. L., Macdonald, T. L., Lynch, K. R. and Brindley, D. N. (2009) Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol. Carcinog. 48, 801-809 CrossRef PubMed.
8. Samadi, N., Gaetano, C., Goping, I. S. and Brindley, D. N. (2009) Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against taxol-induced apoptosis. Oncogene 28, 1028-1039 CrossRef PubMed.
9. Vidot, S., Witham, J., Agarwal, R., Greenhough, S., Bamrah, H. S., Tigyi, G. J., Kaye, S. B. and Richardson, A. (2010) Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. Cell. Signal. 22, 926-935 CrossRef PubMed.
10. Brindley, D. N., Lin, F. T. and Tigyi, G. J. (2013) Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta 1831, 74-85 CrossRef PubMed.
11. Gotoh, M., Fujiwara, Y., Yue, J., Liu, J., Lee, S., Fells, J., Uchiyama, A., Murakami-Murofushi, K., Kennel, S., Wall, J. et al. (2012) Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem. Soc. Trans. 40, 31-36 CrossRef PubMed.
12. Ferry, G., Moulharat, N., Pradere, J. P., Desos, P., Try, A., Genton, A., Giganti, A., Beucher-Gaudin, M., Lonchampt, M., Bertrand, M. et al. (2008) S32826, a nanomolar inhibitor of autotaxin: Discovery, synthesis and applications as a pharmacological tool. J. Pharmacol. Exp. Ther. 327, 809-819 CrossRef PubMed.
13. Lin, M. E., Herr, D. R. and Chun, J. (2010) Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 91, 130-138 CrossRef PubMed.
14. Aoki, J., Taira, A., Takanezawa, Y., Kishi, Y., Hama, K., Kishimoto, T., Mizuno, K., Saku, K., Taguchi, R. and Arai, H. (2002) Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J. Biol. Chem. 277, 48737-48744 CrossRef PubMed.
15. Aoki, J., Inoue, A. and Okudaira, S. (2008) Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta 1781, 513-518 CrossRef PubMed.
16. Tokumura, A., Majima, E., Kariya, Y., Tominaga, K., Kogure, K., Yasuda, K. and Fukuzawa, K. (2002) Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277, 39436-39442 CrossRef PubMed.
17. van Meeteren, L. A., Ruurs, P., Stortelers, C., Bouwman, P., van Rooijen, M. A., Pradere, J. P., Pettit, T. R., Wakelam, M. J., Saulnier-Blache, J. S., Mummery, C. L. et al. (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 26, 5015-5022 CrossRef PubMed.
18. Tanaka, M., Okudaira, S., Kishi, Y., Ohkawa, R., Iseki, S., Ota, M., Noji, S., Yatomi, Y., Aoki, J. and Arai, H. (2006) Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281, 25822-25830 CrossRef PubMed.
19. Gierse, J., Thorarensen, A., Beltey, K., Bradshaw-Pierce, E., Cortes-Burgos, L., Hall, T., Johnston, A., Murphy, M., Nemirovskiy, O., Ogawa, S. et al. (2010) A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J. Pharmacol. Exp. Ther. 334, 310-317 CrossRef PubMed.
20. Giganti, A., Rodriguez, M., Fould, B., Moulharat, N., Coge, F., Chomarat, P., Galizzi, J. P., Valet, P., Saulnier-Blache, J. S., Boutin, J. A. and Ferry, G. (2008) Murine and human autotaxin α, β, and γ isoforms: gene organization, tissue distribution, and biochemical characterization. J. Biol. Chem. 283, 7776-7789 CrossRef PubMed.
21. Hashimoto, T., Okudaira, S., Igarashi, K., Hama, K., Yatomi, Y. and Aoki, J. (2012) Identification and biochemical characterization of a novel autotaxin isoform, ATXδ, with a four-amino acid deletion. J. Biochem. 151, 89-97 CrossRef PubMed.
22. Boutin, J. A. and Ferry, G. (2009) Autotaxin. Cell. Mol. Life Sci. 66, 3009-3021 CrossRef PubMed.
23. Black, E. J., Clair, T., Delrow, J., Neiman, P. and Gillespie, D. A. (2004) Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene 23, 2357-2366 CrossRef PubMed.
24. Azare, J., Doane, A., Leslie, K., Chang, Q., Berishaj, M., Nnoli, J., Mark, K., Al-Ahmadie, H., Gerald, W., Hassimi, M. et al. (2011) STAT3 mediates expression of autotaxin in breast cancer. PLoS ONE 6, e27851 CrossRef PubMed.
25. Moolenaar, W. H., van Meeteren, L. A. and Giepmans, B. N. (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays 26, 870-881 CrossRef PubMed.
26. Kehlen, A., Lauterbach, R., Santos, A. N., Thiele, K., Kabisch, U., Weber, E., Riemann, D. and Langner, J. (2001) IL-1β- And IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 123, 147-154 CrossRef PubMed.
27. Santos, A. N., Riemann, D., Santos, A. N., Kehlen, A., Thiele, K. and Langner, J. (1996) Treatment of fibroblast-like synoviocytes with IFN-γ results in the down-regulation of autotaxin mRNA. Biochem. Biophys. Res. Commun. 229, 419-424 CrossRef PubMed.
28. Clair, T., Aoki, J., Koh, E., Bandle, R. W., Nam, S. W., Ptaszynska, M. M., Mills, G. B., Schiffmann, E., Liotta, L. A. and Stracke, M. L. (2003) Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 63, 5446-5453 PubMed.
29. Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S. and Proia, R. L. (2005) Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25, 11113-11121 CrossRef PubMed.
30. Benesch, M. G., Tang, X., Maeda, T., Ohhata, A., Zhao, Y. Y., Kok, B. P., Dewald, J., Hitt, M., Curtis, J. M., McMullen, T. P. and Brindley, D. N. (2014) Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 28, 2655-2666 CrossRef PubMed.
31. Jasinska, R., Zhang, Q. X., Pilquil, C., Singh, I., Xu, J., Dewald, J., Dillon, D. A., Berthiaume, L. G., Carman, G. M., Waggoner, D. W. and Brindley, D. N. (1999) Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters. Biochem. J. 340, 677-686 CrossRef PubMed.
32. Tomsig, J. L., Snyder, A. H., Berdyshev, E. V., Skobeleva, A., Mataya, C., Natarajan, V., Brindley, D. N. and Lynch, K. R. (2009) Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 419, 611-618 CrossRef PubMed.
33. Albers, H. M., Dong, A., van Meeteren, L. A., Egan, D. A., Sunkara, M., van Tilburg, E. W., Schuurman, K., van Tellingen, O., Morris, A. J., Smyth, S. S. et al. (2010) Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. U.S.A. 107, 7257-7262 CrossRef PubMed.
34. van Meeteren, L. A., Ruurs, P., Christodoulou, E., Goding, J. W., Takakusa, H., Kikuchi, K., Perrakis, A., Nagano, T. and Moolenaar, W. H. (2005) Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J. Biol. Chem. 280, 21155-21161 CrossRef PubMed.
35. van Meeteren, L. A. and Moolenaar, W. H. (2007) Regulation and biological activities of the autotaxin-LPA axis. Prog. Lipid Res. 46, 145-160 CrossRef PubMed.
36. Chun, J., Hla, T., Lynch, K. R., Spiegel, S. and Moolenaar, W. H. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62, 579-587 CrossRef PubMed.
37. Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C. W., Mutoh, T., Lin, M. E., Teo, S. T., Park, K. E., Mosley, A. N. and Chun, J. (2010) LPA receptors: subtypes and biological actions. Annu. Rev. Pharmacol. Toxicol. 50, 157-186 CrossRef PubMed.
38. Bourgoin, S. G. and Zhao, C. (2010) Autotaxin and lysophospholipids in rheumatoid arthritis. Curr. Opin. Investig. Drugs 11, 515-526 PubMed.
39. Dennis, J., Nogaroli, L. and Fuss, B. (2005) Phosphodiesterase-Iα/autotaxin (PD-Iα/ATX): A multifunctional protein involved in central nervous system development and disease. J. Neurosci. Res. 82, 737-742 CrossRef PubMed.
40. Oikonomou, N., Mouratis, M. A., Tzouvelekis, A., Kaffe, E., Valavanis, C., Vilaras, G., Karameris, A., Prestwich, G. D., Bouros, D. and Aidinis, V. (2012) Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 47, 566-574 CrossRef PubMed.
41. Sevastou, I., Kaffe, E., Mouratis, M. A. and Aidinis, V. (2013) Lysoglycerophospholipids in chronic inflammatory disorders: The PLA2/LPC and ATX/LPA axes. Biochim. Biophys. Acta 1831, 42-60 CrossRef PubMed.
42. Iyer, P., Lalane, 3rd, R., Morris, C., Challa, P., Vann, R. and Rao, P. V. (2012) Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PLoS ONE 7, e42627 CrossRef PubMed.
43. Kawagoe, H., Stracke, M. L., Nakamura, H. and Sano, K. (1997) Expression and transcriptional regulation of the PD-Iα/autotaxin gene in neuroblastoma. Cancer Res. 57, 2516-2521 PubMed.
44. Zhao, Z., Xu, S. and Zhang, G. (1999) [A study on expression of autotaxin mRNA in hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 7, 140-141 PubMed.
45. Yang, Y., Mou, L., Liu, N. and Tsao, M. S. (1999) Autotaxin expression in non-small-cell lung cancer. Am. J. Respir. Cell Mol. Biol. 21, 216-222 CrossRef PubMed.
46. Nouh, M. A., Wu, X. X., Okazoe, H., Tsunemori, H., Haba, R., Abou-Zeid, A. M., Saleem, M. D., Inui, M., Sugimoto, M., Aoki, J. and Kakehi, Y. (2009) Expression of autotaxin and acylglycerol kinase in prostate cancer: Association with cancer development and progression. Cancer Sci. 100, 1631-1638 CrossRef PubMed.
47. Panupinthu, N., Lee, H. Y. and Mills, G. B. (2010) Lysophosphatidic acid production and action: Critical new players in breast cancer initiation and progression. Br. J. Cancer 102, 941-946 CrossRef PubMed.
48. Mills, G. B., Eder, A., Fang, X., Hasegawa, Y., Mao, M., Lu, Y., Tanyi, J., Tabassam, F. H., Wiener, J., Lapushin, R. et al. (2002) Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat. Res. 107, 259-283 PubMed.
49. Xu, Y., Fang, X. J., Casey, G. and Mills, G. B. (1995) Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309, 933-940 PubMed.
50. Stracke, M. L., Krutzsch, H. C., Unsworth, E. J., Arestad, A., Cioce, V., Schiffmann, E. and Liotta, L. A. (1992) Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524-2529 PubMed.
51. Yang, S. Y., Lee, J., Park, C. G., Kim, S., Hong, S., Chung, H. C., Min, S. K., Han, J. W., Lee, H. W. and Lee, H. Y. (2002) Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 19, 603-608 CrossRef PubMed.
52. David, M., Wannecq, E., Descotes, F., Jansen, S., Deux, B., Ribeiro, J., Serre, C. M., Gres, S., Bendriss-Vermare, N., Bollen, M. et al. (2010) Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE 5, e9741 CrossRef PubMed.
53. Chen, M., Towers, L. N. and O'Connor, K. L. (2007) LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am. J. Physiol. Cell Physiol. 292, C1927-C1933 CrossRef PubMed.
54. Horak, C. E., Mendoza, A., Vega-Valle, E., Albaugh, M., Graff-Cherry, C., McDermott, W. G., Hua, E., Merino, M. J., Steinberg, S. M., Khanna, C. and Steeg, P. S. (2007) Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res. 67, 11751-11759 CrossRef PubMed.
55. Li, T. T., Alemayehu, M., Aziziyeh, A. I., Pape, C., Pampillo, M., Postovit, L. M., Mills, G. B., Babwah, A. V. and Bhattacharya, M. (2009) β-Arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol. Cancer Res. 7, 1064-1077 CrossRef PubMed.
56. Kim, J. H. and Adelstein, R. S. (2011) LPA1-induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J. Cell. Physiol. 226, 2881-2893 CrossRef PubMed.
57. Du, J., Sun, C., Hu, Z., Yang, Y., Zhu, Y., Zheng, D., Gu, L. and Lu, X. (2010) Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS ONE 5, e15940 CrossRef PubMed.
58. Swamydas, M., Nguyen, D., Allen, L. D., Eddy, J. and Dreau, D. (2011) Progranulin stimulated by LPA promotes the migration of aggressive breast cancer cells. Cell Commun. Adhes. 18, 119-130 CrossRef PubMed.
59. Hausmann, J., Kamtekar, S., Christodoulou, E., Day, J. E., Wu, T., Fulkerson, Z., Albers, H. M., van Meeteren, L. A., Houben, A. J., van Zeijl, L. et al. (2011) Structural basis of substrate discrimination and integrin binding by autotaxin. Nat. Struct. Mol. Biol. 18, 198-204 CrossRef PubMed.
60. Fulkerson, Z., Wu, T., Sunkara, M., Kooi, C. V., Morris, A. J. and Smyth, S. S. (2011) Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J. Biol. Chem. 286, 34654-34663 CrossRef PubMed.
61. Desgrosellier, J. S. and Cheresh, D. A. (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 CrossRef PubMed.
62. Wu, T., Kooi, C. V., Shah, P., Charnigo, R., Huang, C., Smyth, S. S. and Morris, A. J. (2014) Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J. 28, 861-870 CrossRef PubMed.
63. Chen, M. and O'Connor, K. L. (2005) Integrin α6β4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 24, 5125-5130 CrossRef PubMed.
64. Rae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R. and Johnson, M. D. (2007) MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 104, 13-19 CrossRef PubMed.
65. Ellison, G., Klinowska, T., Westwood, R. F., Docter, E., French, T. and Fox, J. C. (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol. Pathol. 55, 294-299 CrossRef PubMed.
66. Chambers, A. F. (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 69, 5292-5293 CrossRef PubMed.
67. Hollestelle, A. and Schutte, M. (2009) Comment re: MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 69, 7893 CrossRef PubMed.
68. Sellappan, S., Grijalva, R., Zhou, X., Yang, W., Eli, M. B., Mills, G. B. and Yu, D. (2004) Lineage infidelity of MDA-MB-435 cells: Expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 64, 3479-3485 CrossRef PubMed.
69. Liu, S., Umezu-Goto, M., Murph, M., Lu, Y., Liu, W., Zhang, F., Yu, S., Stephens, L. C., Cui, X., Murrow, G. et al. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15, 539-550 CrossRef PubMed.
70. Christgen, M., Noskowicz, M., Schipper, E., Christgen, H., Heil, C., Krech, T., Langer, F., Kreipe, H. and Lehmann, U. (2013) Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosomes Cancer 52, 69-80 CrossRef PubMed.
71. Adeyinka, A., Nui, Y., Cherlet, T., Snell, L., Watson, P. H. and Murphy, L. C. (2002) Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res. 8, 1747-1753 PubMed.
72. Boucharaba, A., Serre, C. M., Guglielmi, J., Bordet, J. C., Clezardin, P. and Peyruchaud, O. (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. U.S.A. 103, 9643-9648 CrossRef PubMed.
73. Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., Clezardin, P. and Peyruchaud, O. (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 114, 1714-1725 CrossRef PubMed.
74. Popnikolov, N. K., Dalwadi, B. H., Thomas, J. D., Johannes, G. J. and Imagawa, W. T. (2012) Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma. Tumour Biol. 33, 2237-2243 CrossRef PubMed.
75. Noh, D. Y., Ahn, S. J., Lee, R. A., Park, I. A., Kim, J. H., Suh, P. G., Ryu, S. H., Lee, K. H. and Han, J. S. (2000) Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett. 161, 207-214 CrossRef PubMed.
76. Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A. et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 CrossRef PubMed.
77. Kitayama, J., Shida, D., Sako, A., Ishikawa, M., Hama, K., Aoki, J., Arai, H. and Nagawa, H. (2004) Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6, R640-R646 CrossRef PubMed.
78. Reference deleted.
79. Steeg, P. S., de la Rosa, A., Flatow, U., MacDonald, N. J., Benedict, M. and Leone, A. (1993) Nm23 and breast cancer metastasis. Breast Cancer Res. Treat. 25, 175-187 CrossRef PubMed.
80. Horak, C. E., Lee, J. H., Elkahloun, A. G., Boissan, M., Dumont, S., Maga, T. K., Arnaud-Dabernat, S., Palmieri, D., Stetler-Stevenson, W. G., Lacombe, M. L. et al. (2007) Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res. 67, 7238-7246 CrossRef PubMed.
81. Samadi, N., Bekele, R. T., Goping, I. S., Schang, L. M. and Brindley, D. N. (2011) Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest. PLoS ONE 6, e20608 CrossRef PubMed.
82. Fukui, R., Kato, K., Okabe, K., Kitayoshi, M., Tanabe, E., Fukushima, N. and Tsujiuchi, T. (2012) Enhancement of drug resistance by lysophosphatidic acid receptor-3 in mouse mammary tumor FM3A cells. J. Toxicol. Pathol. 25, 225-228 CrossRef PubMed.
83. Ramachandra, M., Ambudkar, S. V., Chen, D., Hrycyna, C. A., Dey, S., Gottesman, M. M. and Pastan, I. (1998) Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry (Mosc). 37, 5010-5019 CrossRef.
84. Mukai, M., Imamura, F., Ayaki, M., Shinkai, K., Iwasaki, T., Murakami-Murofushi, K., Murofushi, H., Kobayashi, S., Yamamoto, T., Nakamura, H. and Akedo, H. (1999) Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA). Int. J. Cancer. 81, 918-922 CrossRef PubMed.
85. Ishihara, R., Tatsuta, M., Iishi, H., Baba, M., Uedo, N., Higashino, K., Mukai, M., Ishiguro, S., Kobayashi, S. and Murakami-Murofushi, K. (2004) Attenuation by cyclic phosphatidic acid of peritoneal metastasis of azoxymethane-induced intestinal cancers in Wistar rats. Int. J. Cancer 110, 188-193 CrossRef PubMed.
86. Baker, D. L., Fujiwara, Y., Pigg, K. R., Tsukahara, R., Kobayashi, S., Murofushi, H., Uchiyama, A., Murakami-Murofushi, K., Koh, E., Bandle, R. W. et al. (2006) Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem. 281, 22786-22793 CrossRef PubMed.
87. Zhang, H., Xu, X., Gajewiak, J., Tsukahara, R., Fujiwara, Y., Liu, J., Fells, J. I., Perygin, D., Parrill, A. L., Tigyi, G. and Prestwich, G. D. (2009) Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69, 5441-5449 CrossRef PubMed.
88. Schleicher, S. M., Thotala, D. K., Linkous, A. G., Hu, R., Leahy, K. M., Yazlovitskaya, E. M. and Hallahan, D. E. (2011) Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE 6, e22182 CrossRef PubMed.
89. Bhave, S. R., Dadey, D. Y., Karvas, R. M., Ferraro, D. J., Kotipatruni, R. P., Jaboin, J. J., Hallahan, A. N., Dewees, T. A., Linkous, A. G., Hallahan, D. E. and Thotala, D. (2013) Autotaxin inhibition with PF-8380 enhances the radiosensitivity of human and murine glioblastoma cell lines. Front. Oncol. 3, 236 CrossRef PubMed.
90. Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J., Kimura, T., Tobo, M., Yamazaki, Y., Watanabe, T. et al. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64, 994-1005 CrossRef PubMed.
91. David, M., Ribeiro, J., Descotes, F., Serre, C. M., Barbier, M., Murone, M., Clezardin, P. and Peyruchaud, O. (2012) Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol. 40, 1133-1141 PubMed.
92. Marshall, J. C., Collins, J. W., Nakayama, J., Horak, C. E., Liewehr, D. J., Steinberg, S. M., Albaugh, M., Vidal-Vanaclocha, F., Palmieri, D., Barbier, M. et al. (2012) Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J. Natl. Cancer Inst. 104, 1306-1319 PubMed.
93. Boucharaba, A., Guillet, B., Menaa, F., Hneino, M., van Wijnen, A. J., Clezardin, P. and Peyruchaud, O. (2009) Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol. Res. 18, 173-184 CrossRef PubMed.
94. Mao, Y., Keller, E. T., Garfield, D. H., Shen, K. and Wang, J. (2013) Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 32, 303-315 CrossRef PubMed.
95. Su, S. C., Hu, X., Kenney, P. A., Merrill, M. M., Babaian, K. N., Zhang, X. Y., Maity, T., Yang, S. F., Lin, X. and Wood, C. G. (2013) Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma. Clin. Cancer Res. 19, 6461-6472 CrossRef PubMed.
96. Ferry, G., Tellier, E., Try, A., Gres, S., Naime, I., Simon, M. F., Rodriguez, M., Boucher, J., Tack, I., Gesta, S. et al. (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 278, 18162-18169 CrossRef PubMed.
97. Nikitopoulou, I., Oikonomou, N., Karouzakis, E., Sevastou, I., Nikolaidou-Katsaridou, N., Zhao, Z., Mersinias, V., Armaka, M., Xu, Y., Masu, M. et al. (2012) Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J. Exp. Med. 209, 925-933 CrossRef PubMed.
98. Ferguson, C. G., Bigman, C. S., Richardson, R. D., van Meeteren, L. A., Moolenaar, W. H. and Prestwich, G. D. (2006) Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org. Lett. 8, 2023-2026 CrossRef PubMed.
99. Madan, D., Ferguson, C. G., Lee, W. Y., Prestwich, G. D. and Testa, C. A. (2013) Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate. PLoS ONE 8, e79065 CrossRef PubMed.
100. Ghilardi, J. R., Rohrich, H., Lindsay, T. H., Sevcik, M. A., Schwei, M. J., Kubota, K., Halvorson, K. G., Poblete, J., Chaplan, S. R., Dubin, A. E. et al. (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J. Neurosci. 25, 3126-3131 CrossRef PubMed.
101. Pan, H. L., Zhang, Y. Q. and Zhao, Z. Q. (2010) Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons. Mol. Pain 6, 85 CrossRef PubMed.
102. Morimoto, L. M., White, E., Chen, Z., Chlebowski, R. T., Hays, J., Kuller, L., Lopez, A. M., Manson, J., Margolis, K. L., Muti, P. C. et al. (2002) Obesity, body size, and risk of postmenopausal breast cancer: The Women's Health Initiative (United States). Cancer Causes Control 13, 741-751 CrossRef PubMed.
103. Aguas, F., Martins, A., Gomes, T. P., de Sousa, M. and Silva, D. P. (2005) Prophylaxis approach to a-symptomatic post-menopausal women: breast cancer. Maturitas 52 (Suppl. 1), S23-S31 CrossRef PubMed.
104. Steward, W. P. and Brown, K. (2013) Cancer chemoprevention: A rapidly evolving field. Br. J. Cancer. 109, 1-7 CrossRef PubMed.
105. Dusaulcy, R., Rancoule, C., Gres, S., Wanecq, E., Colom, A., Guigne, C., van Meeteren, L. A., Moolenaar, W. H., Valet, P. and Saulnier-Blache, J. S. (2011) Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J. Lipid Res. 52, 1247-1255 CrossRef PubMed.
106. Nishimasu, H., Okudaira, S., Hama, K., Mihara, E., Dohmae, N., Inoue, A., Ishitani, R., Takagi, J., Aoki, J. and Nureki, O. (2011) Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat. Struct. Mol. Biol. 18, 205-212 CrossRef PubMed.
107. Fells, J. I., Lee, S. C., Norman, D. D., Tsukahara, R., Kirby, J. R., Nelson, S., Seibel, W., Papoian, R., Patil, R., Miller, D. D. et al. (2014) Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif. FEBS J. 281, 1017-1028.
108. Fells, J. I., Lee, S. C., Fujiwara, Y., Norman, D. D., Lim, K. G., Tsukahara, R., Liu, J., Patil, R., Miller, D. D., Kirby, R. J. et al. (2013) Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface. Mol. Pharmacol. 84, 415-424 CrossRef PubMed.
109. Kawaguchi, M., Okabe, T., Okudaira, S., Nishimasu, H., Ishitani, R., Kojima, H., Nureki, O., Aoki, J. and Nagano, T. (2013) Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe. ACS Chem. Biol. 8, 1713-1721 CrossRef PubMed.
110. Wang, P., Wu, X., Chen, W., Liu, J. and Wang, X. (2007) The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol. Oncol. 104, 714-720 CrossRef PubMed.
111. Tokumura, A., Kume, T., Fukuzawa, K., Tahara, M., Tasaka, K., Aoki, J., Arai, H., Yasuda, K. and Kanzaki, H. (2007) Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci. 80, 1641-1649 CrossRef PubMed.